Drugs / D-Aspartate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03228524 | Nov 2017 → Jul 2020 | brain injury | Neuromed IRCCS | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03387046 | Mar 2018 → Jan 2019 | relapsing-remitting multiple sclerosis | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D-aspartate | “D-aspartate 2660 milligram (mg) once daily in the form of oral solution for 24 weeks.” NCT03387046 ↗ |
| Known as | D-aspartic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL29757 ↗ |
| Action | Activate | “Asp acts as a neurotransmitter capable of activating the NMDA receptor” NCT03228524 ↗ |
| Modality | Small molecule | — CHEMBL29757 ↗ |
| Route | Oral | “oral D-aspartate (2660 mg, once daily)” NCT03228524 ↗ |